N-methyl-D-aspartate antagonists

Stump, G.L., Lynch, J.J., Macaulay, A., Wafford, K.A., Koblan, K.S. and Liverton, N.J. (2004) NR2B-selective N-methyl-D-aspartate antagonists synthesis and evaluation of 5-substituted benzimidazoles. Journal of Medicinal Chemistry, 47, 2089-2096. 

Malhotra et al. [66] modelled the route of administration-based enhancement of delivery of EAB 515, a hydrophilic N-methyl-D-aspartate antagonist, to the brain. 

Greenamyre JT, O Brien CF (1991) N-methyl-D-aspartate antagonists in the treatment of Parkinson s disease. Arch Neurol 48 977-981... 

Chizh, B. A., Schlutz, H., Scheed, M., Englberger, W. The N-methyl-D-aspartate antagonistic and opioid components of D-methadone antinociception in the rat spinal cord, Neurosci. Lett. 2000, 296, 117-120. 

Ebert, B., Andersen, S Hjeds, H., Dickenson, A. H. Dextropropoxyphene acts as a noncompetitive N-methyl-D-aspartate antagonist, J. Pain Symptom Manage. 1998, 15, 269-274. 

CGP68730A a N-methyl-D-aspartate antagonist acting at the strychnine-insensitive glycine site, Prog. Neuropsychopharmacol. Biol. Psychiatry 2000, 24, 547-670. 

Hisanaga K., Sagar S. M., and Sharp F. R. (1992). N-methyl-D-aspartate antagonists block fos-like protein expression induced via multiple signaling pathways in cultured cortical neurons. J. Neurochem. 58 1836-1844. 

Turski L., Bressler K., Rettig K.-J., Loschmann P.-A., and Wachtel H. (1991). Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 349 414 117. 

Ellison G. (1995). The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res. Rev. 20 250-267. 

Schabitz W. R., Li F., and Fisher M. (2000). The N-methyl-D-aspartate antagonist CNS 1102 protects cerebral gray and white matter from ischemic injury following temporary focal ischemia in rats. Stroke 31 1709-1714. 

Beister A, Kraus P, Kuhn W, Dose M, Weindl A, Gerlach M (2004) The N-methyl-D-aspartate antagonist memantine retards progression of Huntington s disease. J Neural Transm Suppl 117-122. 

Minematsu K, Fisher M, Li L, Sotak CH (1993b) Diffusion and perfusion magnetic resonance imaging studies to evaluate a noncompetitive N-methyl-D-aspartate antagonist and reperfusion in experimental stroke in rats. Stroke 24 2074-2081... 

Buchan A. and Pulsinelli W. A. (1990) Hypothermia but not the N-methyl-D-aspartate antagonist, MK-801, attenuates neuronal damage in gerbils subjected to transient global ischemia. J. Neurosci. 10, 311-316. 

Lecourtier L, Homayoun H, Tamagnan G, Moghaddam B. 2007. Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex. Biol Psychiatry 62 739-746. 

Kinney WA, Abou-Gharbia M, Garrison DT, Schmid J, Kowal DM, Bramlett DR, Miller TL, Tasse RP, Zaleska MM, Moyer JA. Design and synthesis of (2-(8,9-dioxo-2,6-diazabicyclo(5.2.0. non-l(7.-en-2-yl.- ethyl.phosphonic acid (EAA-090., a potent N-methyl-D-aspartate antagonist, via the use of 3-cyclobutene-1,2-dione as an achiral a-amino acid bioisostere. J. Med. Chem. 1998 41 236-246. 

Zarate CA, Singh IB, Carlson PJ, Brutsche NE, Ameli R, Luck-enbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 2006 63 856-864. 

Duan M, Agerman K, Ernfors P, Canlon B. Complementary roles of neurotrophin 3 and a N-methyl-D-aspartate antagonist in the protection of noise and aminoglycoside-induced ototoxicity. Proc Natl Acad Sci USA 2000 97(13) 7597-602. 

Basile AS, Huang JM, Xie C, Webster D, Berlin C, Skolnick P (1996) N-methyl-D-aspartate antagonists limit aminoglycoside antibiotic-induced hearing loss. Nat Med 2 1338-1343. 

Pohl D, Bittigau P, Ishimaru MJ et al (1999) N-Methyl-D-aspartate antagonists and apoptotic cell death triggered by head trauma in developing rat brain. Proc Natl Acad Sci USA 96 2508-2513... 

McDonough JH and Shih T-M (1995). A study of the N -methyl-D-aspartate antagonist properties of anticholinergic drugs. Pharmacol Biochem Behav, 51, 249-253. 

Porsche-Wiebking, E. (1989) New N-methyl-D-aspartate antagonists for the treatment of stroke. Drug Dev. Res. 17 367-375. 

Wieloch, T. (1985). Hypoglycemia induced neuronal damage prevented by an N-methyl-D-aspartate antagonist. Science 230 681-683. 

Koyuncuogiu, H Kara, I., Gunel, M.. et al. (1998). N-methyl-D-aspartate antagonists, glutamate release inhibitors, 4-aininnpy-ridinc at neuromuscular tran.smission. Pharmacol. Res. 37, 485-491. 

Umemura, A., Mabe, H., Nagai, H., Sugino, F. (1992) Action of phospholipases A2 and C on free fatty acid release during complete ischemia in rat neocortex. Effect of phospholipase C inhibitor and N-methyl-D-aspartate antagonist. Journal of Neurosurgery, 76, 648-651. 

Haack, J.A., Rivier, J., Parks, T.N., Mena, E.E., Cruz, L.J., and Olivera, B.M. (1990) Conantokin-T a y-carboxyglutamate containing peptide with N-methyl-D-aspartate antagonist activity. J. Biol. Chem., 265, 6025-6029. 

---